Related Experiment Video
Updated: Jul 11, 2026
07:35
A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva
Published on: July 5, 2017
Future directions in therapeutic interventions for conjunctival inflammatory disorders
Stephen C Pflugfelder1, Michael E Stern
1Ocular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA. stevenp@bcm.tmc.edu
Current Opinion in Allergy and Clinical Immunology
|September 18, 2007
Summary
Recent advances in understanding conjunctival inflammation pathogenesis and treatment offer new hope. Improved drug delivery and targeted therapies are enhancing treatment for inflammatory eye conditions.
Area of Science:
- Ophthalmology
- Immunology
Background:
- Conjunctival inflammation occurs in various conditions like allergy, dry eye, and Stevens-Johnson syndrome.
- Inflammatory mediators play a key role in these disorders.
Purpose of the Study:
- To review recent advances in the pathogenesis of conjunctival inflammatory disorders.
- To examine novel therapeutic strategies for these conditions.
Main Methods:
- Literature review of basic and clinical studies.
- Analysis of identified inflammatory mediators and therapeutic targets.
- Evaluation of new therapeutic agents and drug delivery systems.
Main Results:
- Several inflammatory mediators have been identified as potential therapeutic targets.
- New therapeutic agents and enhanced delivery systems have been developed and assessed.
- Conditions include allergy, atopy, dry eye, mucous membrane pemphigoid, Stevens-Johnson syndrome, and post-surgical inflammation.
Conclusions:
- A deeper understanding of conjunctival inflammation mediators is crucial.
- Improved drug delivery methods enhance therapeutic efficacy.
- These advancements are leading to more effective treatments for inflammatory eye conditions.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...